TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02662907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barium
Description: Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.

Intervention type: DRUG
Group type: OTHER
Intervention: Barium
Description: Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
Study: NCT04471844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune®
Description: Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optune®
Description: Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.
Study: NCT00931138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Aracytine + Daunorubicin)
Description: Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Aracytine + Daunorubicin)
Description: Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
Study: NCT01345643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of hemoglobin level not less than 10g/dL
Description: The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion trigger based on WCPTS
Description: Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
Study: NCT04286386

Intervention type: OTHER
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: OTHER
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: OTHER
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation rating
Description: Acquired 6 times while in MRI-scanner. See Detailed Study Description.
Study: NCT04286386

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI

Intervention type: PROCEDURE
Intervention: Surgical Procedure
Description: Undergo standard of care surgery
Study: NCT01396928

Intervention type: PROCEDURE
Intervention: Colonic reservoir
Description: Type of reservoir to be performed

Intervention type: PROCEDURE
Intervention: Colonic reservoir
Description: Type of reservoir to be performed
Study: NCT02019563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT Group
Description: After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA/FS pulpotomy Group
Description: After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation rating
Description: Acquired 6 times while in MRI-scanner. See Detailed Study Description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FEFA2
Description: Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FEFA2
Description: Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural T1 MRI scan
Description: See Detailed Study Description and Outcome Measures.
Study: NCT03124680

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Opioid free
Description: Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: opioid group
Description: Opioid anesthesia will follow the current standard approach of our hospital.
Study: NCT02348437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair
Description: An on-going suture technique with minimum four stitches.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-repair
Description: The PQ muscle will be placed so it covers the volar plate. No suture.
Study: NCT01877096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A brief motivational interviewing session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
Study: NCT01801384

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Voucher-based incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher-based incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher-based incentives
Study: NCT00544492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter for AV fistula cannulation
Description: catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural T1 MRI scan
Description: See Detailed Study Description and Outcome Measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural T2 MRI scan
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural T2 MRI scan
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DTI MRI scan
Description: See Detailed Study Description and Outcome Measures.
Study: NCT00544492

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter for AV fistula cannulation
Description: catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter for AV fistula cannulation
Description: catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter for AV fistula cannulation
Description: catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DTI MRI scan
Description: See Detailed Study Description and Outcome Measures.
Study: NCT02684292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: brentuximab vedotin
Description: IV infusion
Study: NCT04572230

Intervention type: DEVICE
Intervention: Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Description: The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.

Intervention type: DEVICE
Intervention: Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Description: The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
Study: NCT04072432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-3
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-3
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-3
Description: intravenous administration
Study: NCT01402050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CERVIDIL (Dinoprostone)
Description: INDUCTION OF LABOR
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting state MRI scan
Description: See Detailed Study Description and Outcome Measures.
Study: NCT03079115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose Atorvastatin
Description: high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)

Intervention type: DRUG
Group type: OTHER
Intervention: Conventional-dose Atorvastatin
Description: conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
Study: NCT01868789

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Weightbearing CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Weightbearing CT
Study: NCT00811148

Intervention type: PROCEDURE
Intervention: Tissue Bank
Description: Collection of clinical data and tumor tissue.
Study: NCT00832143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral Card with one-to-one counseling
Description: A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
Study: NCT01305356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augment® Injectable Bone Graft
Description: Implantation of up to 9cc of Augment® Injectable Bone Graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Implantation of up to 9cc of autologous bone graft
Study: NCT05251064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Standard suture wound closure device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clozex
Description: Interlaced adhesive wound closure device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zipline
Description: Adhesive wound closure device using zip-tie like strips.
Study: NCT03348826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 8.4% Solution for Injection
Description: 3 mL injection into line with up to 2 injections administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 8.4% Solution for Injection
Description: 3 mL injection into line with up to 2 injections administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase Injectable Solution
Description: 2 mL injection into line with up to 2 injections administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase Injectable Solution
Description: 2 mL injection into line with up to 2 injections administered
Study: NCT02924675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150mg daily in three doses during three weeks
Study: NCT01402050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FOLEY BALLOON
Description: INDUCTION OF LABOR
Study: NCT03834077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue flossing
Description: Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Conventional physiotherapy in addition to flossing without tension
Study: NCT02804724

Intervention type: OTHER
Intervention: No intervention
Study: NCT03605641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL
Description: JUUL Virginia Tobacco

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VUSE Solo
Description: VUSE SOLO Original

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cigarette
Description: Subject preferred conventional cigarette
Study: NCT03223779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Trifluridine stops DNA replication which may prevent the cancer cells from growing

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon SBRT
Description: SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
Study: NCT01274143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleCARE
Description: Personalized telephone-delivered cancer risk assessment.
Study: NCT03287349

Intervention type: OTHER
Intervention: Blood draw
Description: Two 12.5 mL blood draws

Intervention type: OTHER
Intervention: Photograph
Description: Photograph of severe reaction, will be anonymized
Study: NCT01274143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet intervention
Description: Mailed pamphlet about familial colorectal cancer risk and screening.
Study: NCT00582244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and relaxation
Description: Group A: CBT and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Group B: Physical exercise program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and physical activity
Description: Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control group
Description: Waiting list control group
Study: NCT03287349

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoimmune testing
Description: Autoimmune testing in patients without prior testing
Study: NCT03586609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study: NCT01322633

Intervention type: OTHER
Intervention: Does not apply
Description: This is a non-interventional study, therefore the intervention type / name do not apply.

Intervention type: OTHER
Intervention: Does not apply
Description: This is a non-interventional study, therefore the intervention type / name do not apply.
Study: NCT03921918

Intervention type: DEVICE
Group type: OTHER
Intervention: Breast Pump
Description: Hydraulic Breast pump
Study: NCT03209505

Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Oasys
Description: FDA approved contact lens, fit for daily wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Air Optix Night & Day Aqua
Description: FDA approved contact lens, fit for daily wear
Study: NCT00265226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-dermal administration of Mycobacterium w
Description: Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intra-dermal administration of Mycobacterium w
Description: Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
Study: NCT03673267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutricity
Description: Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
Study: NCT03586609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06398522

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3
Description: Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00768963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg subconjunctival ranibizumab 3 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg subconjunctival ranibizumab at the time of surgery
Study: NCT04598919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinab
Description: 125 mg once daily by mouth for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily by mouth for 24 weeks
Study: NCT02668315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of cord blood expanded with UM171
Description: Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of cord blood expanded with UM171
Description: Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
Study: NCT02924675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses daily with lactose
Study: NCT02946229

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound scan
Description: Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
Study: NCT02668315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of cord blood expanded with UM171
Description: Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
Study: NCT05610761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises with Kegel exercises
Description: Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kegel exercises
Description: Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds).
Study: NCT02430610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife